PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'IAME, Inserm, Université de Paris, UMR1137, 75018 Paris, France.\', \'Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, AP-HP, 75018 Paris, France.\', \'Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, National Institute for Health Research, Imperial College London, London SW7 2AZ, UK.\', \'Service de Virologie, Hôpital Bichat Claude Bernard, AP-HP, 75018 Paris, France.\', \'Department of Neurology and Stroke Center, Hôpital Bichat Claude Bernard, AP-HP, 75018 Paris, France.\', \'Pharmacy Department, Hôpital Bichat Claude Bernard, AP-HP, 75018 Paris, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • 164210.3390/v13081642
?:doi
?:hasPublicationType
?:journal
  • Viruses
is ?:pmid of
?:pmid
?:pmid
  • 34452507
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.805
?:rankingScore_hIndex
  • 52
is ?:relation_isRelatedTo_publication of
?:title
  • Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all